Grant of Share Options (1136Y)

TIDMABH

RNS Number : 1136Y

Angel Biotechnology Holdings Plc

27 February 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Grant of Share Options - Enterprise Management Incentive (EMI) Scheme

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce share options totaling 16,806,723 were awarded to Dr. Stewart White, Commercial Director, under the Company's Enterprise Management Incentive (EMI) share option scheme on 24 February 2012. All share options are exercisable at a price of 0.238p per share, subject to performance and retention criteria being met and are the first share options awarded to Dr. White since his appointment last year.

The exercise dates are as follows:

 
 Exercise Dates             Number of options 
-------------------------  ------------------ 
 04/06/2012 - 03/06/2022    3,361,345 
-------------------------  ------------------ 
 31/12/2012 - 30/12/2022    6,722,689 
-------------------------  ------------------ 
 31/03/2013 - 30/03/2023    6,722,689 
-------------------------  ------------------

Dr Paul Harper, Executive Chairman of Angel Biotechnology Holdings plc said:

"The Board of Directors is delighted to award these options to Dr. White to reflect the commitment made to ensure the success of the Company."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce / Deepak Reddy +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle-upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at www.angelbio.com .

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEUSVVRUOAUUAR

Grafico Azioni Angel Biotechnology (LSE:ABH)
Storico
Da Mag 2024 a Giu 2024